Sirolimus in late acute OKT3-resistant and/or steroid-resistant rejection after simultaneous pancreas and kidney transplantation.
Kahl
A
A
Department of Nephrology, Charité, Campus Virchow-Klinikum, Berlin, Germany.
Oppert
M
M
Müller
A
A
Settmacher
U
U
Lepenies
J
J
Klupp
J
J
Kampf
D
D
Neuhaus
P
P
Frei
U
U
D000328:Adult; D017668:Age of Onset; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery; D003928:Diabetic Nephropathies / Q000601:surgery; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D016035:Pancreas Transplantation / Q000276:immunology*; D006435:Renal Dialysis; D012189:Retrospective Studies; D020123:Sirolimus / Q000627:therapeutic use*; D013256:Steroids / Q000627:therapeutic use; D013997:Time Factors; D014019:Tissue Donors / Q000706:statistics & numerical data
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids; D020123:Sirolimus